Comparative Efficacy and Safety of Different Regimens of Advanced Gastrointestinal Stromal Tumors After Failure Prior Tyrosine Kinase Inhibitors: A Network Meta-Analysis.
Xue ZhangYueqin LiangYanhua LiJiafu YinPublished in: Advances in therapy (2020)
Our results show that ripretinib has the most favorable balance between effectiveness and tolerability among the different treatment regimens for GISTs.